AR047382A1 - Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento - Google Patents

Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento

Info

Publication number
AR047382A1
AR047382A1 ARP050100101A ARP050100101A AR047382A1 AR 047382 A1 AR047382 A1 AR 047382A1 AR P050100101 A ARP050100101 A AR P050100101A AR P050100101 A ARP050100101 A AR P050100101A AR 047382 A1 AR047382 A1 AR 047382A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
halo
secretagogs
useful
Prior art date
Application number
ARP050100101A
Other languages
English (en)
Inventor
Weixu Zhai
Samuel W Gerritz
Charles J Andres
Joseph A Tino
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR047382A1 publication Critical patent/AR047382A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicacion 1:Un compuesto de acuerdo con la formula (1), caracterizado porque cada R1 en cada caso se selecciona independientemente del grupo que consiste de hidrogeno, alquilo, arilo, hidroxi, oxialquilo, oxiperfluoroalquilo, halo, amino, carboaminoalquilo y carboaminocarboalquilo, en donde cada alquilo, arilo oxialquilo, amino, carboaminoalquilo y carboaminocarboalquilo, pueden sustituirse opcionalmente con uno o más alquilo, arilo, hidroxi, oxialquilo, oxiperfluoroalquilo, halo, amino, carboaminalquilo, aminoarboalquilo o carboaminocarboalquilo; R2 se selecciona del grupo que consiste de H y alquilo; R3 en cada caso se selecciona independientemente del grupo que consiste de hidrogeno, alquilo y halo; R4 se selecciona del grupo que consiste de hidrogeno, alquilo y halo; R4 se selecciona del grupo que consiste de H y alquilo X es (CH2)n; y n es 0 o 1, en donde la formula (1) es inclusive todos los profármacos, ésteres de profármacos, estereoisomeros y sales farmacéuticamente aceptables de la formula (1).
ARP050100101A 2004-01-13 2005-01-12 Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento AR047382A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53612804P 2004-01-13 2004-01-13

Publications (1)

Publication Number Publication Date
AR047382A1 true AR047382A1 (es) 2006-01-18

Family

ID=34806987

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100101A AR047382A1 (es) 2004-01-13 2005-01-12 Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento

Country Status (5)

Country Link
US (1) US7214804B2 (es)
AR (1) AR047382A1 (es)
PE (1) PE20051054A1 (es)
TW (1) TW200530181A (es)
WO (1) WO2005070884A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
EA200800710A1 (ru) * 2005-08-31 2008-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
EA019849B1 (ru) * 2006-08-28 2014-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Способ лечения, подавления, ингибирования или уменьшения инцидентов симптомов, ассоциированных с почечным заболеванием: гипогонадизма и непроизвольной потери веса
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
WO2009082437A2 (en) 2007-12-21 2009-07-02 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (sarms) and uses thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2022178228A1 (en) * 2021-02-18 2022-08-25 X-Biotix Therapeutics, Inc. Arylthioether acetamide and related compounds and their use in treating medical conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US6194578B1 (en) 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues

Also Published As

Publication number Publication date
WO2005070884A3 (en) 2006-05-26
PE20051054A1 (es) 2005-12-16
US20050154043A1 (en) 2005-07-14
WO2005070884A2 (en) 2005-08-04
TW200530181A (en) 2005-09-16
US7214804B2 (en) 2007-05-08

Similar Documents

Publication Publication Date Title
AR047382A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
MX2009010024A (es) Nuevo compuesto de adenina.
ECSP045317A (es) Piridinoilpiperidinas como agonistas de 5-ht1f
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
DK2078026T3 (da) Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
RS54533B1 (en) PHENYL AMINOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
WO2008114819A1 (ja) 新規アデニン化合物
AR039672A1 (es) Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat)
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
TW200745117A (en) Macrocylic inhibitors of hepatitis C virus
DOP2003000694A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
CO6280485A2 (es) Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina
TW200612958A (en) Substituted imidazole derivatives
ECSP088773A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
CR9587A (es) Derivados de piridazina
AR086296A1 (es) Derivados de dihidroisoxasol utiles como parasiticidas tanto en animales como en plantas
MY161094A (en) Anti-tumor effect potentiator
NO20082877L (no) Forloperforbindelse til radioaktiv halogenmerket organisk forbindelse
SV2010003459A (es) Derivados de pirimidina 934
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
BR112012014807A2 (pt) "compostos adequados para o tratamento de sinucleopatias"
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
AR111272A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con arilo farmacológicamente activos

Legal Events

Date Code Title Description
FB Suspension of granting procedure